Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities

Nonsteroidal anti-inflammatory drugs in end-stage kidney disease: dangerous or underutilized?

(2021) Kevin S Tang et al.   EXPERT OPINION ON PHARMACOTHERAPY

2020 American College of Rheumatology Guideline for the Management of Gout

(2020) John D. FitzGerald et al.   ARTHRITIS CARE & RESEARCH

Serum Urate Levels of Hemodialyzed Renal Patients Revisited

(2020) María-Dolores Arenas et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis

(2020) Michael D. George et al.   ANNALS OF INTERNAL MEDICINE

Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey

(2020) Lisa K. Stamp et al.   JOURNAL OF RHEUMATOLOGY

Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease

(2020) Markus Sellmayr et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

A cross sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout.

(2020) Thomas Bardin et al.   KIDNEY INTERNATIONAL

Systemic Urate Deposition: An Unrecognized Complication of Gout?

(2020) Puja Khanna et al.   Journal of Clinical Medicine

Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey 2007-2016

(2019) Michael Chen-Xu et al.   Arthritis & Rheumatology

Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease

(2019) Sehrish Ali et al.   Current Atherosclerosis Reports

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

(2019) David Bursill et al.   ANNALS OF THE RHEUMATIC DISEASES

Gout

(2019) Nicola Dalbeth et al.   Nature Reviews Disease Primers

Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout

(2019) Andrea Sabine Klauser et al.   JAMA Cardiology

How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials

(2019) Sarah Stewart et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Design and Rationale for the Veterans Affairs “Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat” Trial

(2018) S. Timilsina et al.   Contemporary Clinical Trials

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

(2018) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert

(2018) Hyon Choi et al.   Arthritis & Rheumatology

Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome

(2018) Simona Mihai et al.   Journal of Immunology Research

Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study

(2018) Estella Yeo et al.   INTERNAL MEDICINE JOURNAL

An Open-Label Dose-Finding Study of Allopurinol to Target Defined Reduction in Urate Levels in Hemodialysis Patients

(2017) Elaine Rutherford et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements

(2017) Lisa K. Stamp et al.   JOURNAL OF RHEUMATOLOGY

Update on colchicine, 2017

(2017) Anastasia Slobodnick et al.   RHEUMATOLOGY

The British Society for Rheumatology Guideline for the Management of Gout

(2017) Michelle Hui et al.   RHEUMATOLOGY

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist

(2017) Marwan H. Adwan   Current Rheumatology Reports

Febuxostat in Hyperuricemic Patients With Advanced CKD

(2016) Doo-Ho Lim et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians

(2016) Amir Qaseem et al.   ANNALS OF INTERNAL MEDICINE

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)

(2016) Thomas Bardin et al.   ANNALS OF THE RHEUMATIC DISEASES

2016 updated EULAR evidence-based recommendations for the management of gout

(2016) P Richette et al.   ANNALS OF THE RHEUMATIC DISEASES

A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis

(2016) Daniel FB Wright et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study)

(2016) Kenneth G. Saag et al.   Arthritis & Rheumatology

Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment

(2016) Kenneth G. Saag et al.   Arthritis & Rheumatology

Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra

(2015) Tania O Crișan et al.   ANNALS OF THE RHEUMATIC DISEASES

Update on Inflammation in Chronic Kidney Disease

(2015) Oleh M. Akchurin et al.   BLOOD PURIFICATION

Allopurinol hypersensitivity: investigating the cause and minimizing the risk

(2015) Lisa K. Stamp et al.   Nature Reviews Rheumatology

Global epidemiology of gout: prevalence, incidence and risk factors

(2015) Chang-Fu Kuo et al.   Nature Reviews Rheumatology

Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies

(2015) Matthew J Roughley et al.   ARTHRITIS RESEARCH & THERAPY

Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin

(2014) Wen-Hung Chung et al.   ANNALS OF THE RHEUMATIC DISEASES

Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease

(2014) Suman Wason et al.   CLINICAL DRUG INVESTIGATION

Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01

(2014) J. Yun et al.   JOURNAL OF IMMUNOLOGY

Clinical Characteristics of and Relationship Between Metabolic Components and Renal Function Among Patients with Early-onset Juvenile Tophaceous Gout

(2014) C.-C. Lu et al.   JOURNAL OF RHEUMATOLOGY

Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review

(2014) Filipe Araújo et al.   RHEUMATOLOGY

Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis

(2014) J. R. Curtis et al.   ARTHRITIS CARE & RESEARCH

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

(2013) Jonathan Kay et al.   ANNALS OF THE RHEUMATIC DISEASES

Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout

(2013) Fernando Perez-Ruiz et al.   ANNALS OF THE RHEUMATIC DISEASES

Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout

(2013) Nicola Dalbeth et al.   BMC MUSCULOSKELETAL DISORDERS

Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response

(2013) J. Yun et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Efficacy and Tolerability of Probenecid as Urate-lowering Therapy in Gout; Clinical Experience in High-prevalence Population

(2013) K. Pui et al.   JOURNAL OF RHEUMATOLOGY

Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008

(2012) Yanyan Zhu et al.   AMERICAN JOURNAL OF MEDICINE

Gout: why is this curable disease so seldom cured?

(2012) Michael Doherty et al.   ANNALS OF THE RHEUMATIC DISEASES

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol

(2012) Lisa K. Stamp et al.   ARTHRITIS AND RHEUMATISM

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

(2012) Abhijit Chakraborty et al.   CLINICAL PHARMACOKINETICS

Reduced Glomerular Function and Prevalence of Gout: NHANES 2009–10

(2012) Eswar Krishnan   PLoS One

Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials

(2011) Robert L. Wortmann et al.   CLINICAL THERAPEUTICS

Statins, inflammation and kidney disease

(2011) Vera Krane et al.   Nature Reviews Nephrology

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study

(2010) Robert A. Terkeltaub et al.   ARTHRITIS AND RHEUMATISM

Mechanisms of inflammation in gout

(2010) Nathalie Busso et al.   ARTHRITIS RESEARCH & THERAPY

Factors Associated With Recurrent Hospital Admissions for Gout

(2009) Ingrid Hutton et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Quality of Life and Disability in Patients with Treatment-Failure Gout

(2009) M. A. BECKER et al.   JOURNAL OF RHEUMATOLOGY

Aspects of Immune Dysfunction in End-stage Renal Disease

(2008) S. Kato et al.   Clinical Journal of the American Society of Nephrology